Repare Therapeutics Inc. (RPTX)

Market Cap	508.50M
Revenue (ttm)	166.67M
Net Income (ttm)	-3.08M
Shares Out	42.09M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,784
Open	12.43
Previous Close	12.27
Day's Range	11.44 - 12.43
52-Week Range	8.02 - 18.68
Beta	0.04
Analysts	Strong Buy
Price Target	18.67 (+54.55%)
Earnings Date	Nov 8, 2023

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 180
• Stock Exchange: NASDAQ
• Ticker Symbol: RPTX

Financial Performance

In 2022, RPTX's revenue was $131.83 million, an increase of 1634.61% compared to the previous year's $7.60 million. Losses were -$29.05 million, -72.83% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price forecast is $18.67, which is an increase of 54.55% from the latest price.

Price Target

$18.67

(54.55% upside)

Analyst Consensus: Strong Buy